Press release: Uppsala,
Dicot will soon report the results from the last part in the clinical phase 1 study. In parallel, preparatory activities are underway to be able to start a clinical phase 2a study in the second half of 2024. An important part of the preparations is the procurement of a Clinical Research Organization to conduct the study. Dicot has now chosen
Furthermore, the American contract manufacturer
"It's great that these important pieces of the puzzle are in place. It also means that we have the pleasure of continuing to collaborate with these two highly professional companies," says
For further information, please contact:
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
https://news.cision.com/dicot-ab--publ-/r/dicot-in-preparation-for-clinical-phase-2a-trial,c3960419
https://mb.cision.com/Main/17172/3960419/2727136.pdf
(c) 2024 Cision. All rights reserved., source